AstraZeneca's Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial

The company states: "Positive high-level results from the open-label Phase III CHAMPION-NMOSD trial showed that Ultomiris achieved a statistically significant and clinically meaningful reduction in the risk of relapse in adults with anti-aquaporin-4 antibody-positive (Ab+) neuromyelitis optica spectrum disorder compared to the external placebo arm from the pivotal Soliris PREVENT clinical trial. Ultomiris, the first and only long-acting C5 complement inhibitor, met the primary endpoint of time to first on-trial relapse, as confirmed by an independent adjudication committee. Notably, no relapse was observed in 58 patients over a median treatment duration of 73 weeks. NMOSD is a rare and devastating autoimmune disease that affects the central nervous system, including the spine and optic nerves. Most people living with NMOSD often experience unpredictable relapses, a new onset of neurologic symptoms or worsening of existing neurologic symptoms, also referred to as attacks, which tend to be severe and recurrent and may result in permanent disability." Reference Link